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9. Drug development 
From some of the sensational reporting about medicines, you might expect medicine 
development to be haphazard with little regard for the safety of animals or humans.  This is 
not in fact the case.  Drug development is precisely regulated and has regard for animals and 
humans.  A general understanding of the processes of drug development should dispel many 
myths about drug development.  
 
Why are drugs developed?  Drugs are developed so that we can turn fatal or non-fatal 
diseases into a routine therapeutic exercise.  For instances, before the development of anti-
hypertensive drugs, hypertension was a fatal disease with people dying in a year or two of 
developing high blood pressure.  Now, millions of people with hypertension are successfully 
managed long term with anti-hypertensive drugs. 
 
Drug development is divided into preclinical and clinical drug development. 
 
 9.1 Preclinical drug discovery 
Preclinical drug discovery is the process before clinical testing of drugs.  The first step in 
preclinical drug development is the discovery or synthesis of a new drug.  At least, 10,000 
new molecules are discovered/synthesized for each successful new drug introduced.  
Extensive preclinical safety and efficacy testing of new drugs are required in animals, and 
this takes an average of 1.5-3 years.    
 There are three main ways in which new drugs are derived; chemical modification, rationale 
drug design, and random screening (Figure 4.1).  Serendipity (accidental discovery of 
something fortunate) may also have a role in drug development. 
 
 
Figure 4.1 Three methods of drug discovery 
 
An important group of drugs that were made by chemical modification were the diuretics.   
However, the initial step was serendipity; an observant physician noticed that sulfanilamide 
(antibiotic) caused a sodium bicarbonate diuresis the loss of sodium, bicarbonate and water 
from the kidney.  Thus, it was reasoned that a sulphanilamide-like drug could be made that 
promoted water loss from the body.  After a string of chemical modification, chlorothiazide 
was synthesised.  Chlorothiazide increases sodium chloride and water excretion.  Further 
modification of the structure of chlorothiazide led to the discovery of frusemide, which is a 
very potent diuretic.  The thiazide diuretics, such as chlorothiazide, and frusemide are 
commonly used in the treatment of hypertension and heart failure to promote water loss. 
 
The second method for drug discovery is rationale drug design, and we will consider a new 
example of this (zanamivir – Relenza).   
 
Rationale drug design usually includes computer design, which is known as in silico.  A 
computer model is made of the site that you want the drug to bind to, and then of the drug 
with best fit for binding.  Then the chemical is synthesised, and then tested pharmacologically 
to determine, whether the chemicals do as predicted.  A drug that was developed in this way 
is zamanivir (Relenza).  Zamanivir can prevent or shorten the flu, which is a virus.  
Neuramidinase is an enzyme involved in viral replication, and the structure of this enzyme 
has been determined.  The structure shows a pocket, where we may be able to get a drug in to 
inhibit the enzyme.  Zamanivir binds in the pocket to inhibit the activity of neuramidinase, 
and consequently the replication of the flu virus. 
 
A third approach to drug discovery is random screening.  This uses high-throughput 
screening managed by robotics.  There is random screening for biological activity.  For 
instance, if you wanted to develop a H2-receptor antagonist the chemicals would be screened 
for activity at H2-receptors.  The screening may be of banks of previously discovered 
chemicals, or of natural products, or of libraries of peptides and nucleic acids. 
 
 4.2 Pharmacological profiling 
Once a lead compound has been discovered (e.g. a drug with activity at a certain biding site), 
the compound undergoes pharmacological profiling.  A large number of experiments are 
undertaken, mainly using animals, to determine the pharmacodynamics and pharmacokinetics 
of the drug.  Questions asked include; Does the drug do what we expect?  Does it do anything 
else?  Is it active after oral administration?  The initial profiling usually depends on the 
pharmacological goal e.g. anti-infectives will be tested against infectious organisms.  Anti-
diabetic drugs will be tested for their ability to lower blood glucose in animal models of 
diabetes. 
 
 4.3 Safety and toxicity 
New drugs undergo extensive safety and toxicity testing in animals.  This testing was 
increased after the thalidomide disaster.  Thalidomide was developed as a hypnotic 
(calming) and anti-emetic drug in the 1950s.  It was used as a hypnotic and extensively to 
prevent morning sickness.  For severe morning sickness, it was more beneficial than any 
other drugs available at the time.  Limited toxicity testing in rats had suggested it was safe in 
pregnancy.  To women who took thalidomide during pregnancy, 10,000 children were born 
with phocomelia, which is the absence of arms or legs with hands or feet attached to body 
trunk.  Obviously, when it was shown that thalidomide was the causative agent, it was 
withdrawn and litigation followed, costing the pharmaceutical company responsible to pay 
millions in compensation. 
 
What was learnt from the thalidomide disaster?  The animal rights movement claimed that the 
thalidomide disaster showed that the testing of drugs in animals was not predictive of toxicity 
in humans, and should be abandoned.  Toxicity testing should be in humans. 
 
There is another interpretation.  Birth defects are rare in rats.  Rats are more likely to reabsorb 
defective foeti.  Closer analysis of toxicity testing of thalidomide showed lower litter 
numbers, which probably indicated the potential to cause birth defects in humans.  More 
extensive toxicity in animals probably would have prevented the thalidomide tragedy.  More 
extensive toxicity in animals is now undertaken. 
 
This preclinical safety and toxicity testing takes two to five years, and involves the collection 
and analysis of lots of data.  This testing is closely supervised by an independent Animal 
Ethics Committee that works to minimise the number of animals used, and the harm done to 
animals.  Acute toxicity of single doses and chronic toxicity of repeated doses of drugs is 
often tested on mice.  The effects of drugs on reproductive function and teratogenicity (ability 
to cause birth defects) are tested in a variety of animal species.  For drugs that are going to be 
used long term in chronic illness, the carcinogenic potential has to be tested in animals 
longterm.  Mutagenic potential is undertaken in bacteria. 
 
 4.4 Clinical trials – introduction 
At some stage in the drug development procedure, a drug patent has to be applied for, to 
protect your discovery from other companies.  Patents are valid for 15-17 years.  During the 
patent, all monies made by that drug are returned to the pharmaceutical company that 
invested in the development.  However as preclinical testing takes on average 1.5 to 5 years, 
and clinical trialling take 5 to 7 years on average, there may not be much time for the 
developing company to recoup their investment.  After a patent expires, the generic drug can 
be made by other companies, commonly known as generic companies.  The generic 
companies make drugs but they do not pay towards the development of the drug.  After the 
patent expires, the pharmaceutical company that discovered the drug, no longer receives all 
the money from that drug.  
 
After successful preclinical testing, a few new drugs enter the next stage, which is clinical 
trialling.  Clinical trials are experiments in humans to evaluate drugs, medical devices, 
biologics etc.  Thus, clinical trials are to evaluate interventions in general.  The results of 
clinical trials are presented to the authorities for assessment.  This assessment is carried out 
be the Federal Drug Administration (FDA) in US, or the Therapeutic Goods Administration 
(TGA) in Australia.  If the FDA or TGA accept that the drug does more good than harm, it is 
registered for clinical use.  The clinical development of drugs does not stop at registration, as 
there is ongoing preclinical and clinical assessment.  It is presently considered that it costs 
A$1.2 billion for a single, successful new drug. 
 
Only about 10% of compounds that enter clinical trial are approved/registered for sale.  
Clinical trials are under stringent law enforced guidelines.  These guidelines include ethics, 
which is assessed by human ethics committee, and patient consent.  For patient consent, they 
must be fully informed in lay language of exactly what is happening in the trial.  Clinical 
trials of drugs are often funded by pharmaceutical company with independent investigators.  
Without this funding, there would be little development of new drugs.  There is some 
government funding available for clinical trials of complementary and alternative medicines 
in the US, which allows these medicines to be properly evaluated.  Clinical trials are not 
quick, as they take 7-9 years. 
 
4.5 Ethics in clinical trials 
The atrocities of the Nazis on concentration camp inmates, such as cutting people and seeing 
how long they bled for, were investigated after World War II in Nuremberg Tribunal.  The 
tribunal developed the Nuremberg Code, which is started the modern era of ethics.  There are 
4 main aspects of modern ethics.  Firstly, there is non-maleficence, which means to do no 
harm.  The second aspect, is the reverse of this, it is beneficence, which is to do good.  
Combining non-maleficence and beneficence means that clinical trials have to maximize 
benefits and minimize harm to the patient.  The third aspect of ethics in clinical trials is 
justice, which means that the benefits of research should be distributed fairly, not just to the 
rich and powerful.  The fourth aspect is respect for person.  This has three parts, Firstly, 
individuals be regarded as autonomous agents, and their opinions and choices respected, 
regardless of how daft or illogical they are.  The second part is veracity, the truth must be 
told to participants.  Participants have to be able to understand the clinical trial, and the 
benefits and risks, and these are provide in a Plain Language Statement, prior to consent 
being asked for.  Finally, confidentiality, the participants name, details etc are to be kept 
confidential. 
 
Ethics are policed by IRBs, Institutional Research Boards, which are also known as Ethics 
committee.  This process involves peer review of proposed research.  Peer review is 
independent review of the proposed clinical trial to determine whether the trial is appropriate.  
Universities often have ethics committees both for peer reviewing animal experiments and 
human experiments.  For instance, QUT has a Human Research Ethics committee, an 
Animal Ethics committee and a Biosafety committee. 
 
 4.6 Clinical trial design 
There are a number of factors that make a good clinical trial design.  There should be 
similarity of the control group, who do not receive the drug, with the group receiving the 
intervention (drug).  Otherwise any difference between the control and intervention group, 
may be due to other differences between the groups, other than due to the drug intervention.  
One way of achieving similarity between groups is the random assignment of patients to 
control and intervention group.  In initial clinical trials, the control group was untreated 
whereas the treated group were given the drug.  This is almost guaranteed to show a 
beneficial effect with the drug, as people like to believe the drug is going to do them good.  
To avoid this, the control group are given an inert replica of the drug, which is known as the 
placebo.  Placebos are very good for you!  The placebo response (which means “I shall 
please”) is 40% of relief of pain in labour, and up to 60% in relieving depression.  This is the 
key reason for not accepting anecdotal evidence, and requiring placebo-controlled clinical 
trials. 
 
Another danger in clinical trials is observer bias.  The observer of the patients will want the 
patient to get better and will be looking for signs of benefit with the drug, which may or may 
not be present.  To avoid this problem, blinding is used.  There are two types of blinding.  In 
single blinded clinical trials, only the study participants are blinded, not the investigator, and 
this happens when it is considered important that the investigator knows which participant 
has the active drug.  In double-blinded clinical trials, neither the participants nor the 
investigator know who is taking the active drug.  The best design for a clinical trial is the 
randomized, double-blind, placebo-controlled trial.  Such a trial has the highest likelihood 
of revealing the truth about the effects of a drug.  The randomized, double-blind, placebo 
controlled trial has a very simple design (Figure 4.2). 
 
Figure 4.2 Randomized, double-blind, placebo-controlled trial (Copyright QUT, Sheila 
Doggrell) 
 
In a randomized, double-blind, placebo-controlled trial, the selected patient population is 
randomised to either the placebo (dummy tablet) or the drug, and the health of the 
participants is monitored. 
 
 4.7 Phases of clinical trials 
In drug development, it mandated that new drugs have to go through 4 Phases with each 
phase having different requirements.  Clinical trialling starts with small numbers of 
participants and is mainly to test safety, and only when some safety has been established, 
does testing in larger numbers of participants occur. 
 Phase I clinical trials are often performed in University Hospitals using experts in clinical 
pharmacology.  They are open with both subject and observer knowing what is happening.  
Phase I clinical trials use small numbers (20-80) of healthy volunteers.  The exception to this 
is when testing toxic drugs for cancer and HIV.  As these would be toxic to healthy 
volunteers, the Phase I testing of cancer and HIV drugs is in patients.  The dose tested in 
Phase I will be a small fraction of that shown to cause toxicity in animals.  The main reason 
for the trial is to establish safety, and the trial will measure toxicity and, possibly, efficacy.  
In Phase I, provided an assay is available to measure the drug, blood samples may be taken to 
measure the pharmacokinetics of the drug.  If a drug shows unacceptable toxicity, the clinical 
trialling will stop after Phase I. 
 
Phase II clinical trials are also often performed in University Hospitals using experts.  They 
are single-blinded i.e. they use placebo/dummy tablets to prevent the subject knowing which 
is active drug, but the physician does know which is the active drug.  Phase II trials may have 
a comparison with standard treatment.  If there is a standard drug available for a certain 
conditions, it has to be established that the new drug is better than the standard drug before it 
can be registered.  Phase II trials are in 10-200 patients with the disease the drug is indicated 
for.  The Phase II trial is to establish the efficacy and toxicity of the drugs.  This information 
is needed for more extensive Phase III trialling.  If a drug does not show efficacy in Phase II 
trialling, it will not go forward to Phase III. 
 
Phase III clinical trials are usually performed in the setting the drug will eventually be used 
in.  Thus, if a drug is to be used in hospital, it will be tested in hospital, whereas if a drug is 
used in general practice, it will be tested in general practice.  The investigators are usually 
specialists in the disease being treated.  Phase III trials are double-blinded; neither the 
observer nor the subject knows which is active drug.  A third person holds the code 
identifying the drug, which is not broken until the trial is completed.  Phase III trials enrol 
large numbers of patients, and are expensive.  Phase III clinical trials establish efficacy and 
toxicity. 
 
Positive results in Phase III lead to applications for registration to market the drug to the 
Therapeutics Goods Administration (TGA).   
 
Phase IV clinical trialling is also known as post-marketing surveillance.  Even though 
Phase III trials enrol large numbers of patients, this may not be large enough to detect any 
rare or long-term adverse effects, and this is done in Phase IV.  Phase IV is under the actual 
conditions the drug will be used.  It is monitoring safety in large numbers of patients and over 
longer periods of time than previous Phase.  Phase IV clinical trials, especially the monitoring 
of adverse effects, involves, all health professionals, not just investigators. 
 
4.8 Therapeutics Goods Administration 
The Therapeutic Goods Regulations (TGA) is responsible for the quality, safety, efficacy, 
and timely availability of drugs and medical devices in Australia.  The TGA regulates 
prescription, over-the-counter and complementary medicines.  It usually accepts the 
recommendations coming from the Australian Drug Evaluation Committee (ADEC).  
ADEC is a committee of specialists that are able to evaluate pharmaceutical and chemical 
data, animal pharmacology and toxicology data, and clinical data.  Applications are usually 
100,000 pages in length, and the review by physicians/scientists takes up to 3 years.   For 
serious conditions, may get approval earlier in the trialling process and in a shorter time.  
After registration, drugs can be administered to patients outside of clinical trials at full cost. 
 
 4.9 Pharmaceutical Benefits Scheme 
After registration, drugs are available at full cost.  Only drugs that accepted into the 
Pharmaceutical Benefits Scheme (PBS) are subsidised as part of Medicare.  Before 
acceptance onto the PBS, a pharmacoeconomic analysis is done.  This analysis weighs up 
the benefits of the drug against the cost to the government (Medicare).  Broadly speaking, 
they are asking “are you worth it”.  One of the drugs discussed extensively in the press 
recently is Herceptin (trastuzumab).   Trastuzumab is very useful in certain types of breast 
cancer.  However, the full cost is $60,000/year.  Initially, women with this type of breast 
cancer could only have the treatment, if they paid for it.  Under the PBS, trastuzumab is 
$33/prescription. 
 
